Literature DB >> 17785199

New insights into RSK activation and hematopoietic cancer.

Ana Cuadrado1, Angel R Nebreda.   

Abstract

The tyrosine kinase receptor FGFR3 is thought to play a role in hematopoietic malignancies. A new study in this issue of Cancer Cell identifies the serine/threonine kinase RSK2 as a key substrate of FGFR3 in human t(4;14)-positive multiple myeloma (MM) cells. Constitutively active FGFR3 directly phosphorylates RSK2 on Tyr529, which primes RSK2 for activation by the kinases ERK1 and ERK2 (ERK1/2). In turn, RSK2 activity plays an important role in the survival of FGFR3-expressing MM cells.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17785199     DOI： 10.1016/j.ccr.2007.08.017

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  7 in total

1.  Mechanism of sustained activation of ribosomal S6 kinase (RSK) and ERK by kaposi sarcoma-associated herpesvirus ORF45: multiprotein complexes retain active phosphorylated ERK AND RSK and protect them from dephosphorylation.

Authors:  Ersheng Kuang; Fayi Wu; Fanxiu Zhu
Journal:  J Biol Chem       Date:  2009-03-20       Impact factor: 5.157

2.  Insights into the inhibition of the p90 ribosomal S6 kinase (RSK) by the flavonol glycoside SL0101 from the 1.5 Å crystal structure of the N-terminal domain of RSK2 with bound inhibitor.

Authors:  Darkhan Utepbergenov; Urszula Derewenda; Natalya Olekhnovich; Gabriela Szukalska; Budhaditya Banerjee; Michael K Hilinski; Deborah A Lannigan; P Todd Stukenberg; Zygmunt S Derewenda
Journal:  Biochemistry       Date:  2012-08-06       Impact factor: 3.162

3.  p90RSK2 is essential for FLT3-ITD- but dispensable for BCR-ABL-induced myeloid leukemia.

Authors:  Shannon Elf; Dean Blevins; Lingtao Jin; Tae-Wook Chung; Ifor R Williams; Benjamin H Lee; Jian-Xin Lin; Warren J Leonard; Jack Taunton; Hanna J Khoury; Sumin Kang
Journal:  Blood       Date:  2011-04-28       Impact factor: 22.113

4.  Identification of quercitrin as an inhibitor of the p90 S6 ribosomal kinase (RSK): structure of its complex with the N-terminal domain of RSK2 at 1.8 Å resolution.

Authors:  Urszula Derewenda; Mykhaylo Artamonov; Gabriela Szukalska; Darkhan Utepbergenov; Natalya Olekhnovich; Hardik I Parikh; Glen E Kellogg; Avril V Somlyo; Zygmunt S Derewenda
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2013-01-19

5.  Bacterial Expression, Purification and In Vitro Phosphorylation of Full-Length Ribosomal S6 Kinase 2 (RSK2).

Authors:  Darkhan Utepbergenov; Paulina M Hennig; Urszula Derewenda; Mykhaylo V Artamonov; Avril V Somlyo; Zygmunt S Derewenda
Journal:  PLoS One       Date:  2016-10-12       Impact factor: 3.240

6.  Interactions between FGFR2 and RSK2-implications for breast cancer prognosis.

Authors:  Dominika Czaplinska; Kamil Mieczkowski; Anna Supernat; Andrzej C Skladanowski; Radzislaw Kordek; Wojciech Biernat; Anna J Zaczek; Hanna M Romanska; Rafal Sadej
Journal:  Tumour Biol       Date:  2016-07-30

7.  Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells.

Authors:  Anna L Stratford; Christopher J Fry; Curtis Desilets; Alastair H Davies; Yong Y Cho; Yvonne Li; Zigang Dong; Isabelle M Berquin; Philippe P Roux; Sandra E Dunn
Journal:  Breast Cancer Res       Date:  2008-11-27       Impact factor: 6.466
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.